In this episode, we’re going to talk with AllerScripts, Director of Allergy, Robert Erskine, to touch on Subcutaneous Immunotherapy, also called SCIT.

Learn how it can be an effective form of treatment when looking to reduce patients' sensitivity to allergens.

Robert Erskine received a Bachelors of Science in Microbiology from Texas A&M University and completed three years of postgraduate study at Harvard Medical School, Division of Medical Sciences Immunology program. During his career, he has gained extensive experience in the use of allergenic extracts for allergy skin testing and immunotherapy, and he has been invited to lecture at numerous allergy fellowship training programs in the US and Canada.

Robert also has ten years of laboratory research experience with appointments at the University of Texas Southwestern Medical Center, Harvard University, and Biogen.

Follow us on Social Media
LinkedIn
Facebook
Instagram

About Innovation Compounding

Innovation Compounding is licensed as a 503A, compounding pharmacy, accredited by The Pharmacy Compounding Accreditation Board (PCAB®).

Today, we support over 7,000 prescribers, 70,000+ patients, and annually provide 100,000+ prescriptions to most states across the U.S. 

We commit to individualized pharmaceutical care by being relentless in our drive for personalized medicine, compassionate toward our patients and doctors, and being a #WellnessAdvocate for our patients’ lives and state of well being.

Learn more about the work we do and how we can help to build your practice by visiting us online:

Innovation Compounding Website

Support the show